Brookline Capital Markets Estimates Opus Genetics Q2 Earnings

Opus Genetics, Inc. (NASDAQ:IRD) – Equities researchers at Brookline Capital Markets issued their Q2 2026 earnings per share estimates for shares of Opus Genetics in a report released on Wednesday, June 10th. Brookline Capital Markets analyst K. Raja forecasts that the company will earn ($0.18) per share for the quarter. The consensus estimate for Opus Genetics’ current full-year earnings is ($0.97) per share. Brookline Capital Markets also issued estimates for Opus Genetics’ Q3 2026 earnings at ($0.18) EPS.

IRD has been the subject of a number of other research reports. Wedbush upped their target price on shares of Opus Genetics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. Citizens Jmp reduced their target price on Opus Genetics from $12.00 to $11.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. Leerink Partners assumed coverage on Opus Genetics in a report on Thursday, May 21st. They issued an “outperform” rating and a $10.00 target price on the stock. Wall Street Zen cut Opus Genetics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Opus Genetics in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.67.

Opus Genetics Stock Performance

Shares of IRD stock opened at $3.89 on Thursday. Opus Genetics has a 52-week low of $0.90 and a 52-week high of $5.81. The firm has a market capitalization of $321.18 million, a PE ratio of -2.92 and a beta of 0.56. The stock has a fifty day simple moving average of $4.81 and a two-hundred day simple moving average of $3.63.

Opus Genetics (NASDAQ:IRD) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.59). Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 892.36%.The business had revenue of $2.16 million during the quarter, compared to analysts’ expectations of $2.93 million.

Insider Transactions at Opus Genetics

In other news, Director Fighting Blindness Foundation sold 1,700,000 shares of Opus Genetics stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $4.35, for a total value of $7,395,000.00. Following the sale, the director directly owned 3,792,171 shares of the company’s stock, valued at approximately $16,495,943.85. The trade was a 30.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Robert E. Gagnon sold 7,842 shares of Opus Genetics stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $5.18, for a total value of $40,621.56. Following the completion of the sale, the chief financial officer directly owned 592,158 shares in the company, valued at $3,067,378.44. This trade represents a 1.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 1,773,395 shares of company stock valued at $7,777,278. 11.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. OMERS ADMINISTRATION Corp purchased a new position in Opus Genetics in the fourth quarter worth about $177,000. Johnson Investment Counsel Inc. purchased a new position in Opus Genetics in the fourth quarter worth about $40,000. Raymond James Financial Inc. grew its position in Opus Genetics by 95.6% in the third quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock worth $37,000 after acquiring an additional 11,000 shares in the last quarter. Virtu Financial LLC purchased a new position in Opus Genetics in the fourth quarter worth about $34,000. Finally, Comerica Bank purchased a new position in Opus Genetics in the first quarter worth about $29,000. Hedge funds and other institutional investors own 14.97% of the company’s stock.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.